All inspectors · Key sources (PDF) · Antithrombotics sheet (PDF)
The Antithrombotic Therapy Around PCI one-pagerOpen it in a new tab

The patient in front of you

Mrs. K., 77, with hypertension, presented with 5 hours of chest pain at rest, ST depression in V2–V4 and a rising troponin. Angiography the next day showed a single 90% stenosis of the proximal left anterior descending artery, treated with a drug-eluting stent by radial access. She was loaded with aspirin and ticagrelor. She has never bled and takes no anticoagulant; eGFR 48, hemoglobin 12.6 g/dL, platelets 214, ejection fraction 55%, sinus rhythm. The antithrombotic course follows her from admission to her 12-month visit; each trial answers one decision in her care.

This page helps you decide: Ticagrelor or prasugrel for her NSTEMI?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

For Mrs. K., ISAR-REACT 5 points the same way for a prasugrel strategy (60 mg once her anatomy was known, then 5 mg daily at 77) as for the whole trial: in her age-or-weight group death, MI or stroke was 12.7% vs 14.6% and serious bleeding 8.1% vs 10.6%, but neither difference was significant, the trial was open label, and the label still says age ≥75 generally not recommended unless diabetes or prior MI. Ticagrelor, which she received, remains a COR 1 choice. On the one-pager ISAR-REACT 5 sits on page 1, in the “Which P2Y12 inhibitor?” box (Head to head row).